PI-RADS 3类病灶的判读与管理:减少不确定性并指导前列腺癌诊断决策
本文围绕前列腺MRI中诊断难度较高的PI-RADS 3类病灶展开,讨论其定义、诊断意义及导致其比例增高的因素,包括图像质量不佳、治疗后改变、非对比增强成像和阅片者经验不足。文章提出通过结构化报告、PI-RADS决策规则、加强图像质控和整合前列腺特异性抗原密度等策略,可减少不确定性并优化活检决策。
要点
- PI-RADS 3类病灶对临床有意义前列腺癌的可能性不确定,易致过度诊断和过度治疗。
- 图像质量不佳、治疗后改变、非对比增强成像和经验不足会增加PI-RADS 3类病灶比例。
- 整合前列腺特异性抗原密度等辅助生物标志物有助于细化PI-RADS 3类病灶的活检决策。
核心结论
- 充分理解PI-RADS 3类病灶的局限性、促成因素及进展中的管理策略,有助于减少不必要干预并提高临床有意义前列腺癌的检出。
研究设计与样本
- 本文为叙述性综述,围绕前列腺MRI中PI-RADS 3类病灶的定义、成因、管理策略及新兴方法展开讨论,未报告系统检索或样本量。
关键影像表现/征象
- PI-RADS 3类病灶代表临床有意义前列腺癌的模棱两可可能性。
- 结构化报告和PI-RADS决策规则有助于减少前列腺MRI评分的判读不确定性。
诊断标准与关键数值
- PI-RADS 3类病灶的定义为临床有意义前列腺癌可能性不确定的病灶。
- 避免非对比增强成像、改善图像质量及提升阅片者经验可降低PI-RADS 3类病灶比例。
- 前列腺特异性抗原密度可作为整合进风险分层路径的辅助标志物,以细化PI-RADS 3类病灶的活检选择。
临床应用与阅片要点
- 在日常报告中遇到PI-RADS 3类病灶时,应结合图像质量、序列完整性和患者准备情况判断评分可靠性。
- 阅片时应评估是否存在治疗后改变或操作后改变对前列腺MRI表现的影响。
- 对PI-RADS 3类病灶可引入前列腺特异性抗原密度等风险因素,以分层决定是否进一步活检。
局限性
- PI-RADS 3类病灶本身即表示模棱两可的临床有意义前列腺癌风险,临床决策困难。
- 图像质量不佳、非对比增强成像及阅片者经验不足可导致PI-RADS 3类病灶比例增高。
- 本文为叙述性综述,未提供系统检索方案、纳入标准或定量合并分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Prostate Imaging Reporting and Data System (PI-RADS) category 3 lesions are one of the most diagnostically challenging lesion types in prostate MRI interpretation and management. These lesions represent an equivocal likelihood of clinically significant prostate cancer. Because of this uncertainty in clinical decision making, PI-RADS 3 lesions are associated with a higher risk of overdiagnosis and overtreatment. The authors discuss the definition and related diagnostic implications of PI-RADS 3 lesions and describe factors associated with a higher prevalence of PI-RADS 3 lesions, including suboptimal image quality, postprocedural and treatment changes, use of noncontrast imaging, and less-experienced readers. Addressing these issues by using structured reporting, applying PI-RADS decision rules, enhancing reader experience, establishing image quality assessment, and implementing patient preparation strategies can reduce uncertainty in the scoring of prostate MRI examination findings. Also, integrating ancillary biomarkers such as prostate-specific antigen density into a risk-based diagnostic pathway may help refine biopsy decisions for patients with PI-RADS 3 lesions. A thorough understanding of the limitations related to, factors contributing to, and evolving management strategies for PI-RADS 3 lesions enables physicians to make better informed clinical decisions, reduce unnecessary interventions, and improve detection of clinically significant prostate cancer. Ongoing challenges and emerging approaches are highlighted to improve the assessment and management of men with PI-RADS 3 prostate MRI lesions.
引用
- Nicola, Correia, Antunes, et al. Navigating PI-RADS 3 Lesions: Reducing Uncertainty and Guiding Prostate Cancer Diagnostic Decision Making. Radiographics. 2026. PMID: 42658725. doi:10.1148/rg.250170
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。